NovoCure’s EF-32 Optune® Trial Reaches Completion, Setting Up a Key Catalyst for NVCR Investors
TipRanks (Mon, 30-Mar 12:30 PM ET)
TipRanks (Fri, 27-Mar 6:20 AM ET)
Market Chameleon (Thu, 26-Mar 5:19 AM ET)
4 stocks to watch on Thursday: MSFT, LITE, MARA, NVCR
Seeking Alpha News (Thu, 26-Mar 8:53 AM ET)
Novocure mid-stage trial for electric fields device succeeds in pancreatic cancer
Seeking Alpha News (Thu, 26-Mar 7:43 AM ET)
NovoCure Announces Positive Phase 2 PANOVA-4 Pancreatic Cancer Data
TipRanks (Thu, 26-Mar 7:32 AM ET)
Business Wire (Thu, 26-Mar 7:00 AM ET)
Analysts Conflicted on These Healthcare Names: TELA Bio (TELA), NovoCure (NVCR) and Incyte (INCY)
TipRanks (Wed, 25-Mar 7:21 AM ET)
Business Wire (Mon, 2-Mar 7:00 AM ET)
Novocure to Participate in 2026 Leerink Global Healthcare Conference
Business Wire (Fri, 27-Feb 4:30 PM ET)
NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.
Novocure Limited - trades on the NASDAQ stock market under the symbol NVCR.
As of March 30, 2026, NVCR stock price declined to $10.36 with 1,213,772 million shares trading.
NVCR has a beta of 1.18, meaning it tends to be more sensitive to market movements. NVCR has a correlation of 0.11 to the broad based SPY ETF.
NVCR has a market cap of $1.16 billion. This is considered a Small Cap stock.
Last quarter Novocure Limited - reported $174 million in Revenue and -$.22 earnings per share. This beat revenue expectation by $1 million and exceeded earnings estimates by $.19.
In the last 3 years, NVCR traded as high as $83.60 and as low as $9.82.
The top ETF exchange traded funds that NVCR belongs to (by Net Assets): VTI, VB, IWM, VBK, VXF.
NVCR has underperformed the market in the last year with a price return of -45.4% while the SPY ETF gained +12.7%. NVCR has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -23.1% and -14.1%, respectively, while the SPY returned -8.2% and -4.3%, respectively.
NVCR support price is $10.49 and resistance is $11.45 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that NVCR shares will trade within this expected range on the day.
